Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTY: Biweekly vs Triweekly Docetaxel in Metastatic Hormone Refractory Prostate Cancer
NCT00255606Phase 3Completed
- Sponsor
- Tampere University
- Start
- Aug 2005
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa), sponsored by Tampere University. Primary endpoint: Time to treatment failure. Started Aug 2005; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00255606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255606.